Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VALOR: VLA15 Lyme Disease Vaccine in Healthy Participants ≥5 Years
NCT05477524Phase 3Completed
- Sponsor
- Pfizer
- Start
- Aug 2022
- Primary completion
- Jan 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 7
01
Overview
A Phase 3 trial of VLA15 in Lyme disease, sponsored by Pfizer. Started Aug 2022; status: completed.
02
Drugs
VLA15
03
Conditions
Lyme disease
Beyond the preview
Go deeper on NCT05477524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05477524.